The more I have looked into cardio oncology thanks to our spotlight on Professor Aaron and Zantrene’s protective properties the more I’m surprised at how big a gap there is in this field.
Watching another online presentation today (below) respected cardio oncologist from MD Anderson cancer centre (who RAC have collaborated with before.) mention it is only recently that they moved cardiologists into the oncology area, before they might have been in separate parts of the hospital, and cardiologists were dealing with cancer treatment damage after treatment, whereas now they are focusing on earlier stages.
MD Anderson previous connection to RAC.
https://www.raceoncology.com/md-anderson-cancer-center-researchers-publish-aml-preclinical-study-on-bisantrene-drug-combinations/
Ann: Race releases cardioprotection market potential data, page-203
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.73 |
Change
-0.105(5.74%) |
Mkt cap ! $293.8M | |||
| Open | High | Low | Value | Volume |
| $1.82 | $1.82 | $1.70 | $240.3K | 138.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 270 | $1.73 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.75 | 3000 | 1 |
View Market Depth
| Last trade - 16.10pm 22/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |